A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
- 12 April 2011
- journal article
- phase i-studies
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 30 (3), 1096-1106
- https://doi.org/10.1007/s10637-011-9666-9
Abstract
Objective The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589) when administered as a single agent to adult patients with advanced solid tumors or cutaneous T-cell lymphoma whose disease had progressed despite standard therapy or for whom no standard therapy existed. Methods Panobinostat was administered orally once daily on Monday, Wednesday, and Friday of each week. A total of 13 patients were treated with one of three initial doses: 10 mg (n = 3), 15 mg (n = 4), or 20 mg (n = 6). Results No dose-limiting toxicity was observed in 12 evaluable patients. The most frequently reported adverse events, regardless of whether they were related to the study drug, were diarrhea and nausea in 10 patients (76.9%). Thrombocytopenia was reported in 12 of 13 patients (92.3%). Five of 11 patients (45.4%) had stable disease. Conclusion Panobinostat administered orally once daily on Monday, Wednesday, and Friday of each week was well tolerated at doses up to 20 mg in Japanese patients. Dose escalation did not proceed after exploration of the 20 mg dose due to emerging global clinical data at that time.Keywords
This publication has 19 references indexed in Scilit:
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challengesCancer Letters, 2009
- Clinical Studies of Histone Deacetylase InhibitorsClinical Cancer Research, 2009
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancerAnnals Of Oncology, 2007
- Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphomaJournal of Clinical Oncology, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589Clinical Cancer Research, 2006
- Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic MalignanciesJournal of Clinical Oncology, 2006
- Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial ResultsJournal of Clinical Oncology, 2001